"Onyx Pharma: Kyprolis Is Still A Smokin' Hot Multiple Myeloma Drug"
See Adam Feuerstein's writeup today. Some of this should start to rub off on LGND.
"Ligand is eligible to receive milestone and royalty payments, as well as revenue from sales of Captisol from this program"
ONXX projects approx a 250% increase for Kyprolis revenue in '13, or about $200M. At 3% in royalty+material sales, LGND will get ~$6M from Kyprolis in '13. Revenue flow will continue to increase out to 2017-18 as Kyprolis increases its market penetration.